Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2015, Article ID 728494, 9 pages
http://dx.doi.org/10.1155/2015/728494
Research Article

Restoration of Endothelial Function in Pparα−/− Mice by Tempol

University of Missouri-Kansas City School of Medicine, Kansas City, MO 64108, USA

Received 19 August 2015; Revised 16 October 2015; Accepted 20 October 2015

Academic Editor: Nanping Wang

Copyright © 2015 Neerupma Silswal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. Staels, W. Koenig, A. Habib et al., “Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators,” Nature, vol. 393, no. 6687, pp. 790–793, 1998. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Hiukka, M. Maranghi, N. Matikainen, and M.-R. Taskinen, “PPARα: an emerging therapeutic target in diabetic microvascular damage,” Nature Reviews Endocrinology, vol. 6, no. 8, pp. 454–463, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. J. H. J. Taverne, A. J. J. C. Bogers, D. J. Duncker, and D. Merkus, “Reactive oxygen species and the cardiovascular system,” Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 862423, 15 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Tabernero, K. Schoonjans, L. Jesel, I. Carpusca, J. Auwerx, and R. Andriantsitohaina, “Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation,” BMC Pharmacology, vol. 2, article 10, 2002. View at Google Scholar · View at Scopus
  5. L. G. Cervantes-Pérez, M. D. L. L. Ibarra-Lara, B. Escalante et al., “Endothelial nitric oxide synthase impairment is restored by clofibrate treatment in an animal model of hypertension,” European Journal of Pharmacology, vol. 685, no. 1–3, pp. 108–115, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Silswal, N. K. Parelkar, M. J. Wacker, M. Brotto, and J. Andresen, “Phosphatidylinositol 3,5-bisphosphate increases intracellular free Ca2+ in arterial smooth muscle cells and elicits vasocontraction,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 300, no. 6, pp. H2016–H2026, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. J. J. Andresen, N. I. Shafi, W. Durante, and R. M. Bryan Jr., “Effects of carbon monoxide and heme oxygenase inhibitors in cerebral vessels of rats and mice,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 1, pp. H223–H230, 2006. View at Publisher · View at Google Scholar · View at Scopus
  8. R. M. Bryan Jr., J. You, S. C. Phillips et al., “Evidence for two-pore domain potassium channels in rat cerebral arteries,” American Journal of Physiology—Heart and Circulatory Physiology, vol. 291, no. 2, pp. H770–H780, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. N. K. Parelkar, N. Silswal, K. Jansen, J. Vaughn, R. M. Bryan Jr., and J. Andresen, “2,2,2-Trichloroethanol activates a nonclassical potassium channel in cerebrovascular smooth muscle and dilates the middle cerebral artery,” Journal of Pharmacology and Experimental Therapeutics, vol. 332, no. 3, pp. 803–810, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Silswal, C. D. Touchberry, D. R. Daniel et al., “FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability,” The American Journal of Physiology— Endocrinology and Metabolism, vol. 307, no. 5, pp. E426–E436, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Silswal, N. K. Parelkar, M. J. Wacker, M. Badr, and J. Andresen, “PPARα-independent arterial smooth muscle relaxant effects of PPARα agonists,” PPAR Research, vol. 2012, Article ID 302495, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. A. M. Beyer, W. J. de Lange, C. M. Halabi et al., “Endothelium-specific interference with peroxisome proliferator activated receptor gamma causes cerebral vascular dysfunction in response to a high-fat diet,” Circulation Research, vol. 103, no. 6, pp. 654–661, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. C. M. Halabi, A. M. Beyer, W. J. de Lange et al., “Interference with PPARγ function in smooth muscle causes vascular dysfunction and hypertension,” Cell Metabolism, vol. 7, no. 3, pp. 215–226, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. L. V. d’Uscio, T. He, A. V. R. Santhanam, L.-J. Tai, R. M. Evans, and Z. S. Katusic, “Mechanisms of vascular dysfunction in mice with endothelium-specific deletion of the PPAR-delta gene,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 306, no. 7, pp. H1001–H1010, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Hu, Y. Chen, L. Ding et al., “Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 38, pp. 15401–15406, 2013. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Ismail-Beigi, T. Craven, M. A. Banerji et al., “Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial,” The Lancet, vol. 376, no. 9739, pp. 419–430, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Sharma, S. Sellers, N. Stefanovic et al., “Direct endothelial nitric oxide synthase activation provides atheroprotection in diabetes-accelerated atherosclerosis,” Diabetes, vol. 64, no. 11, pp. 3937–3950, 2015. View at Publisher · View at Google Scholar
  18. M. Madigan and B. Zuckerbraun, “Therapeutic potential of the nitrite-generated NO pathway in vascular dysfunction,” Frontiers in Immunology, vol. 4, article 174, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. K. Goya, S. Sumitani, X. Xu et al., “Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 4, pp. 658–663, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. B. S. Fleenor, D. R. Seals, M. L. Zigler, and A. L. Sindler, “Superoxide-lowering therapy with TEMPOL reverses arterial dysfunction with aging in mice,” Aging Cell, vol. 11, no. 2, pp. 269–276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Ding, R. Cheng, Y. Hu et al., “Peroxisome proliferatore activated receptor a protects capillary pericytes in the retina,” The American Journal of Pathology, vol. 184, no. 10, pp. 2709–2720, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. A. Gunnett, Y. Chu, D. D. Heistad, A. Loihl, and F. M. Faraci, “Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase,” The American Journal of Physiology—Heart and Circulatory Physiology, vol. 275, no. 2, pp. H416–H421, 1998. View at Google Scholar · View at Scopus
  23. A. M. Briones, M. J. Alonso, J. Marin, and M. Salaices, “Role of iNOS in the vasodilator responses induced by L-arginine in the middle cerebral artery from normotensive and hypertensive rats,” British Journal of Pharmacology, vol. 126, no. 1, pp. 111–120, 1999. View at Publisher · View at Google Scholar · View at Scopus
  24. C. A. Gunnett, D. D. Lund, A. K. McDowell, F. M. Faraci, and D. D. Heistad, “Mechanisms of inducible nitric oxide synthase-mediated vascular dysfunction,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 8, pp. 1617–1622, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. P. J. H. Smeets, B. E. J. Teunissen, P. H. M. Willemsen et al., “Cardiac hypertrophy is enhanced in PPAR alpha-/- mice in response to chronic pressure overload,” Cardiovascular Research, vol. 78, no. 1, pp. 79–89, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Obih and A. Oyekan, “Regulation of blood pressure, natriuresis and renal thiazide/amiloride sensitivity in PPARα null mice,” Blood Pressure, vol. 17, no. 1, pp. 55–63, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. J. L. Wilson, R. Duan, A. El-Marakby, A. Alhashim, and D. L. Lee, “Peroxisome proliferator activated receptor- agonist slows the progression of hypertension, attenuates plasma interleukin-6 levels and renal inflammatory markers in angiotensin II infused mice,” PPAR Research, vol. 2012, Article ID 645969, 7 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Olukman, E. D. Sezer, S. Ülker, E. Y. Sözmen, and G. M. Çınar, “Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats,” Experimental Diabetes Research, vol. 2010, Article ID 828531, 10 pages, 2010. View at Publisher · View at Google Scholar
  29. A. Y. Y. Cheng and L. A. Leiter, “PPAR-alpha: therapeutic role in diabetes-related cardiovascular disease,” Diabetes, Obesity and Metabolism, vol. 10, no. 9, pp. 691–698, 2008. View at Publisher · View at Google Scholar · View at Scopus
  30. A. Avogaro, M. Miola, A. Favaro et al., “Gemfibrozil improves insulin sensitivity and flow-mediated vasodilatation in type 2 diabetic patients,” European Journal of Clinical Investigation, vol. 31, no. 7, pp. 603–609, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. Evans, R. A. Anderson, J. Graham et al., “Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus,” Circulation, vol. 101, no. 15, pp. 1773–1779, 2000. View at Publisher · View at Google Scholar · View at Scopus
  32. D. A. Playford, G. F. Watts, J. D. Best, and V. Burke, “Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus,” The American Journal of Cardiology, vol. 90, no. 11, pp. 1254–1257, 2002. View at Publisher · View at Google Scholar · View at Scopus
  33. K. Tordjman, C. Bernal-Mizrachi, L. Zemany et al., “PPARα deficiency reduces insulin resistance and atherosclerosis in apoE-null mice,” The Journal of Clinical Investigation, vol. 107, no. 8, pp. 1025–1034, 2001. View at Publisher · View at Google Scholar · View at Scopus